The R-Pharm Group has entered into an agreement with the Chinese company CCTQ to bring the oncology drug catequentinib to the Russian market, the Russian manufacturer’s press service reported. “R-Pharm has concluded an agreement with CCTQ, one of the leaders of the Chinese pharmaceutical market, to bring to the Russian market a drug for the treatment of solid tumors with the active ingredient catequentinib. Under the terms of the agreement, the final stages of production will be localized at R-Pharm’s facilities,” the statement said (quoted via TASS). Registration of the drug in Russia is expected in 2027.
Catequentinib, also known as anlotinib, is a multiple tyrosine kinase inhibitor (TKI) for oral use. By blocking these proteins, catequentinib halts the process of uncontrolled division of cancer cells, and the tumor stops growing. It is prescribed in later lines of therapy for non-small cell and small cell lung cancer, as well as soft tissue sarcoma.
The molecule was originally developed by the American research company Advenchen Laboratories. Later, the rights for its development and commercialization were acquired by the Chinese company CTTQ (a part of Sino Biopharmaceutical). CTTQ conducted the main clinical trials and brought the drug to the Chinese market in 2018 under the brand name Focus V.
